143 related articles for article (PubMed ID: 36823994)
1. Prophylaxis with recombinant von Willebrand factor in patients with type 3 von Willebrand disease: Results of a post hoc analysis from a phase 3 trial.
Leebeek FWG; Peyvandi F; Tiede A; Castaman G; Escobar M; Wang M; Zülfikar B; Susen S; Miesbach W; Wang S; Wang Y; Zhang J; Özen G
Eur J Haematol; 2023 Jul; 111(1):29-40. PubMed ID: 36823994
[TBL] [Abstract][Full Text] [Related]
2. Recombinant von Willebrand factor prophylaxis in patients with severe von Willebrand disease: phase 3 study results.
Leebeek FWG; Peyvandi F; Escobar M; Tiede A; Castaman G; Wang M; Wynn T; Baptista J; Wang Y; Zhang J; Mellgård B; Özen G
Blood; 2022 Jul; 140(2):89-98. PubMed ID: 35439298
[TBL] [Abstract][Full Text] [Related]
3. An evaluation of von Willebrand factor (recombinant) therapy for adult patients living with severe type 3 von Willebrand disease.
Hancock JM; Escobar MA
Expert Rev Hematol; 2023 Mar; 16(3):157-161. PubMed ID: 36861346
[TBL] [Abstract][Full Text] [Related]
4. Preclinical evaluation of recombinant von Willebrand factor in a canine model of von Willebrand disease.
Schwarz HP; Dorner F; Mitterer A; Mundt W; Schlokat U; Pichler L; Turecek PL
Wien Klin Wochenschr; 1999 Mar; 111(5):181-91. PubMed ID: 10226348
[TBL] [Abstract][Full Text] [Related]
5. Phase 3 study of recombinant von Willebrand factor in patients with severe von Willebrand disease who are undergoing elective surgery.
Peyvandi F; Mamaev A; Wang JD; Stasyshyn O; Timofeeva M; Curry N; Cid AR; Yee TT; Kavakli K; Castaman G; Sytkowski A
J Thromb Haemost; 2019 Jan; 17(1):52-62. PubMed ID: 30362288
[TBL] [Abstract][Full Text] [Related]
6. Hemostatic efficacy, safety, and pharmacokinetics of a recombinant von Willebrand factor in severe von Willebrand disease.
Gill JC; Castaman G; Windyga J; Kouides P; Ragni M; Leebeek FW; Obermann-Slupetzky O; Chapman M; Fritsch S; Pavlova BG; Presch I; Ewenstein B
Blood; 2015 Oct; 126(17):2038-46. PubMed ID: 26239086
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of recombinant von Willebrand factor in a canine model of von Willebrand disease.
Schwarz HP; Dorner F; Mitterer A; Mundt W; Schlokat U; Pichler L; Turecek PL
Haemophilia; 1998; 4 Suppl 3():53-62. PubMed ID: 10028320
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic-Pharmacodynamic Comparison of Recombinant and Plasma-Derived von Willebrand Factor in Patients with von Willebrand Disease Type 3.
Bauer A; Friberg-Hietala S; Smania G; Wolfsegger M
J Blood Med; 2023; 14():399-411. PubMed ID: 37332615
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and safety of a novel recombinant human von Willebrand factor manufactured with a plasma-free method: a prospective clinical trial.
Mannucci PM; Kempton C; Millar C; Romond E; Shapiro A; Birschmann I; Ragni MV; Gill JC; Yee TT; Klamroth R; Wong WY; Chapman M; Engl W; Turecek PL; Suiter TM; Ewenstein BM;
Blood; 2013 Aug; 122(5):648-57. PubMed ID: 23777763
[TBL] [Abstract][Full Text] [Related]
10. In vivo characterization of recombinant von Willebrand factor in dogs with von Willebrand disease.
Turecek PL; Gritsch H; Pichler L; Auer W; Fischer B; Mitterer A; Mundt W; Schlokat U; Dorner F; Brinkman HJ; van Mourik JA; Schwarz HP
Blood; 1997 Nov; 90(9):3555-67. PubMed ID: 9345039
[TBL] [Abstract][Full Text] [Related]
11. von Willebrand factor/factor VIII concentrate (Wilate) prophylaxis in children and adults with von Willebrand disease.
Sidonio RF; Boban A; Dubey L; Inati A; Kiss C; Boda Z; Lissitchkov T; Nemes L; Novik D; Peteva E; Taher AT; Timofeeva MA; Vilchevska KV; Vdovin V; Werner S; Knaub S; Djambas Khayat C
Blood Adv; 2024 Mar; 8(6):1405-1414. PubMed ID: 38237075
[TBL] [Abstract][Full Text] [Related]
12. Outcomes in Patients With von Willebrand Disease Receiving Recombinant von Willebrand Factor on Demand and in Surgical Settings: Chart Review.
Sun SX; Lowndes S; Willock R; Jones C; Brighton S
Clin Appl Thromb Hemost; 2023; 29():10760296231177294. PubMed ID: 37282513
[TBL] [Abstract][Full Text] [Related]
13. Recombinant vs plasma-derived von Willebrand factor to prevent postpartum hemorrhage in von Willebrand disease.
Machin N; Ragni MV
Blood Adv; 2020 Jul; 4(14):3234-3238. PubMed ID: 32692849
[TBL] [Abstract][Full Text] [Related]
14. Switch to pdVWF:pdFVIII concentrate for prophylaxis in a paediatric patient with Type 3 von Willebrand disease: a case report.
Berger C; Thouvenin S; Montmartin A; Noyel P; Legendre C; Tardy-Poncet B
Hematology; 2023 Dec; 28(1):2186332. PubMed ID: 36892261
[TBL] [Abstract][Full Text] [Related]
15. Clinical Efficacy and Safety of Fanhdi
Jiménez-Yuste V; Alvarez-Román MT; Palomo Bravo Á; Galmes BJ; Nieto Hernández MDM; Benítez Hidalgo O; Marzo Alonso C; Pérez González NF; Coll J; Núñez R; Carrasco M; García Candel F; Gonzalez-Porras JR; Hernández García C; Varó Castro MJ; Mir R
Clin Appl Thromb Hemost; 2022; 28():10760296221074348. PubMed ID: 35108125
[TBL] [Abstract][Full Text] [Related]
16. A personalized approach to the management of VWD.
Phua CW; Berntorp E
Transfus Apher Sci; 2019 Oct; 58(5):590-595. PubMed ID: 31466808
[TBL] [Abstract][Full Text] [Related]
17. Exposure-Response Relationship between VWF/FVIII Activity and Spontaneous Bleeding Events Following Recombinant VWF Prophylaxis in Severe VWD.
Leebeek FWG; Castaman G; Marier JF; Özen G; Bhattacharya I; Zhang J; Wang S; Wang Y
TH Open; 2024 Apr; 8(2):e243-e251. PubMed ID: 38938750
[No Abstract] [Full Text] [Related]
18. An Open-Label Extension Study to Assess the Long-Term Efficacy and Safety of a Plasma-Derived von Willebrand Factor (VWF)/Factor VIII (FVIII) Concentrate in Patients with von Willebrand Disease (SWIFT-VWDext Study).
Lissitchkov T; Klukowska A; Buevich E; Maltceva I; Auerswald G; Stasyshyn O; Seifert W; Rogosch T
J Blood Med; 2020; 11():345-356. PubMed ID: 33117020
[TBL] [Abstract][Full Text] [Related]
19. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.
Michiels JJ; van Vliet HH; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van der Velden A; Budde U
Clin Appl Thromb Hemost; 2007 Jan; 13(1):14-34. PubMed ID: 17164493
[TBL] [Abstract][Full Text] [Related]
20. A phase III study comparing secondary long-term prophylaxis versus on-demand treatment with vWF/FVIII concentrates in severe inherited von Willebrand disease.
Peyvandi F; Castaman G; Gresele P; De Cristofaro R; Schinco P; Bertomoro A; Morfini M; Gamba G; Barillari G; Jiménez-Yuste V; Königs C; Iorio A; Federici AB
Blood Transfus; 2019 Sep; 17(5):391-398. PubMed ID: 30747707
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
